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Regulation of MBD1-mediated transcriptional
repression by SUMO and PIAS proteins
Matthew J Lyst, Xinsheng Nan1
and Irina Stancheva*
Wellcome Trust Centre for Cell Biology, University of Edinburgh,
Edinburgh, UK
In mammalian cells, DNA methylation is associated with
heritable and stable gene repression, mediated in part by
methyl-CpG-binding domain (MBD) proteins that recruit
corepressors to modify chromatin. MBD1 protein, a mem-
ber of the MBD family, forms a complex with SETDB1
histone methylase to silence transcription at target pro-
moters by methylation of lysine 9 of histone H3. How
MBD1-mediated transcriptional repression is regulated is
currently unknown. Here we show that MBD1 is a target
for sumoylation by PIAS1 (Protein Inhibitors of Activated
STAT 1) and PIAS3 E3 SUMO (small ubiquitin-like modi-
fier)-ligases, at two conserved lysine residues within the
C-terminus of MBD1. Although sumoylated MBD1 binds
to methylated DNA, it does not incorporate into a complex
with SETDB1 and does not efficiently repress transcription
of a target gene, p53BP2, in HeLa cells. Our data suggest
that transcriptional silencing by MBD1 is regulated by a
PIAS-mediated conjugation of SUMO1, which antagonizes
the formation of a repressive complex with SETDB1.
The EMBO Journal (2006) 25, 5317–5328. doi:10.1038/
sj.emboj.7601404; Published online 26 October 2006
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Introduction
Methylation of cytosine at CpG dinucleotides is the major
epigenetic modification in vertebrate genomes and contri-
butes to the maintenance of genome stability, regulation
of gene expression and normal progression through
development (Meehan and Stancheva, 2001; Bird, 2002).
Approximately 70% of all CpG dinucleotides are methylated
in mammalian somatic cells. Methylated CpGs are randomly
distributed throughout the genome, but are normally
excluded from promoter-associated CpG-rich sequences
known as CpG islands (Bird, 2002). In human cancers,
aberrant methylation of CpG islands results in stable and
heritable gene silencing, mediated by a family of proteins that
contain a methyl-CpG-binding domain (MBD) (Bird and
Wolffe, 1999; Jones and Baylin, 2002). The MBD family
comprises MBD1, MBD2, MBD3, MeCP2 and MBD4
(Hendrich and Bird, 1998). Transcriptional repression by
MBD proteins operates through recruitment of corepressor
complexes that modify chromatin into an inactive state (Bird
and Wolffe, 1999; Prokhortchouk and Hendrich, 2002).
Histone deacetylase and histone methylase (HMT) corepres-
sor activities have been found stably or transiently associated
with MBD proteins (Nan et al, 1998; Zhang et al, 1999; Fuks
et al, 2003; Sarraf and Stancheva, 2004).
MBD1 is the largest protein in the MBD family. It contains
a conserved N-terminal MBD domain, three centrally located
CxxC motifs and a C-terminal transcriptional repression
domain (TRD). The third CxxC motif has DNA-binding prop-
erties independent of the MBD domain, with preferential
recognition of nonmethylated CpG-rich DNA (Jorgensen
et al, 2004). Several splice variants of MBD1 have been
identified in human and mouse cells and shown to differ in
the number of CxxC motifs and the length of the region
between the last CxxC motif and the TRD (Fujita et al, 1999;
Jorgensen et al, 2004). An isoform with two CxxC motifs
(CxxC2 and CxxC3) is the most abundant MBD1 protein in
HeLa cells and a variety of other human cell lines (Cross et al,
1997).
Transcriptional repression by MBD1 is largely histone
deacetylation-independent and operates through the recruit-
ment of histone H3 lysine 9 (H3K9) methylase SETDB1
and SETDB1 cofactor AM/MCAF1 to chromatin (Ng et al,
2000; Fujita et al, 2003a; Sarraf and Stancheva, 2004). An
interaction between MBD1 and another H3K9 methylase,
Suv39H1, has also been reported (Fujita et al, 2003b).
H3K9 methylation was found at virtually all MBD1 binding
sites, including silenced gene promoters, suggesting that the
MBD1/SETDB1 complex silences transcription by introducing
repressive methylation of H3K9 (Sarraf and Stancheva, 2004).
It was further shown that migrating replication forks desta-
bilize the interaction of MBD1 with methylated DNA to
promote the assembly of a transient S-phase-specific complex
between MBD1/SETDB1 and the major subunit p150 of
chromatin assembly factor CAF-1. The MBD1-dependent
recruitment of SETDB1 to the postreplicative chromatin
assembly machinery is crucial for the maintenance of H3K9
methylation in synchrony with DNA methylation and for
the stable epigenetic inheritance of silenced chromatin
(Sarraf and Stancheva, 2004).
We wondered what mechanisms might permit regulation
of MBD1-mediated maintenance of gene silencing. Such
regulation may be particularly important during cell differ-
entiation and development, when gene expression patterns
and chromatin states undergo significant changes. Poten-
tially, post-translational modifications of MBD proteins
could either change the affinity of the MBD domain for
methylated DNA or affect the assembly of MBDs into com-
plexes with corepressor proteins. As an example of the first
possibility, phosphorylation of MeCP2 has been observed as
a result of calcium-dependent membrane depolarization in
Received: 21 April 2006; accepted: 5 October 2006; published online:
26 October 2006
*Corresponding author. Wellcome Trust Centre for Cell Biology,
University of Edinburgh, Michael Swann Building, Mayfield Road,
Edinburgh EH9 3JR, UK. Tel.: þ 44 131 650 7029;
Fax: þ 44 131 650 7360; E-mail: istancheva@ed.ac.uk
1Present address: MRC Clinical Sciences Centre, Imperial College
London, Hammersmith Hospital Campus, Du Cane Road,
London W12 0NN, UK
The EMBO Journal (2006) 25, 5317–5328 | & 2006 European Molecular Biology Organization | All Rights Reserved 0261-4189/06
www.embojournal.org
&2006 European Molecular Biology Organization The EMBO Journal VOL 25 | NO 22 | 2006
 
EMBO
 
THE
JOURNAL
5317
cortical neurons (Chen et al, 2003; Martinowich et al, 2003).
Phosphorylated MeCP2 dissociates from methylated CpGs at
the BDNF promoter, facilitating activation of BDNF transcrip-
tion. However, there are no known examples of specific post-
translational modifications that either promote or destabilize
the interactions of MBDs with partner proteins.
Modification of nuclear proteins by SUMO (Small
Ubiquitin-like Modifier) has been shown to play a role in
transcriptional regulation (Johnson, 2004; Hay, 2005). SUMO
can be attached enzymatically to a variety of proteins,
including transcription factors, histones and chromatin-
related proteins (Girdwood et al, 2003; Shiio and Eisenman,
2003; Hay, 2005). Sumoylation of target proteins usually
occurs at a lysine residue within the consensus sites CKxE,
where C is a large hydrophobic amino acid (L, I or V) and
x can be any amino acid. Conjugation of SUMO to target
substrates is mechanistically similar to ubiquitination, but
uses SUMO-specific enzymatic machinery, which includes E1
SUMO-activating enzyme formed by a heterodimer Aos1/
Uba2, an E2 SUMO conjugation enzyme Ubc9 and E3 ligases
such as RanBP2 and PIAS (Protein Inhibitors of Activated
STAT) family proteins. E3 enzymes transfer SUMO from Ubc9
to specific protein substrates (Schwienhorst et al, 2000;
Johnson, 2004; Hay, 2005). Unlike ubiquitination, sumoyla-
tion of target proteins does not promote protein degradation
and in many cases stabilizes modified proteins (Desterro
et al, 1998; Ulrich, 2005). However, the effects of SUMO
conjugation are diverse and largely dependent on the
function of the protein targeted for sumoylation. Like other
post-translational protein modifications, sumoylation can
either promote or inhibit the formation of specific protein
complexes, affect subnuclear localization of proteins and
regulate transcription both positively and/or negatively
(Sachdev et al, 2001; Girdwood et al, 2003; Johnson, 2004;
Long et al, 2004; Pastushok and Xiao, 2004; Gomez-del Arco
et al, 2005; Hay, 2005).
In this report, we demonstrate that in human cells MBD1
protein is modified by SUMO1 at two conserved sites sur-
rounding lysines K450 and K489 within the MBD1 C-termi-
nus. We identify PIAS1 and PIAS3 as the E3 SUMO ligases,
which directly interact with MBD1 and are required for
sumoylation of MBD1 in vivo. Sumoylated MBD1 does not
efficiently incorporate into a complex with SETDB1, resulting
in derepression of the MBD1 target gene p53BP2. Our data
suggest that assembly of the MBD1/SETDB1 repressive com-
plex is controlled by a competition between SETDB1 and the
SUMO conjugation machinery for binding to MBD1. The
outcome of this competition is dependent on the protein
levels of SETDB1 and PIAS1/3 SUMO ligases and provides
a potential mechanism for flexible regulation of MBD1-
mediated gene silencing.
Results
MBD1 is modified by SUMO1
We previously performed a yeast two-hybrid screen using
human MBD1 as bait against a HeLa cDNA library to identify
MBD1-interacting proteins (Sarraf and Stancheva, 2004).
From this screen, we isolated and characterized two MBD1-
binding partners—SETDB1 HMT and p150 subunit of chro-
matin assembly factor CAF-1. From the same screen, we also
recovered nine plasmids that contained cDNAs encoding the
E3 SUMO ligases PIAS1 and PIAS3. The putative interaction
of MBD1 with PIAS proteins prompted us to investigate
whether MBD1 protein is SUMO-modified in human cells.
The conjugation of SUMO to target proteins creates branched
protein molecules migrating with higher molecular weight
than the unmodified protein in acrylamide gels. To investi-
gate whether MBD1 is sumoylated in vivo, we prepared
nuclear extracts, with or without the SUMO isopeptidase
inhibitor N-ethyl maleimide (NEM), from HeLa, MRC5 pri-
mary human lung fibroblasts and NCI-H226 lung carcinoma
cells. Western blots with anti-MBD1 antibodies detected a
major 70 kDa MBD1 band in all nuclear extracts (Figure 1A).
An additional B130 kDa band could be seen only in extracts
prepared with NEM, suggesting that it may represent a
SUMO-modified form of MBD1. A third band, migrating
slightly slower than the major 70 kDa MBD1 protein, could
also be seen in all extracts, irrespectively whether prepared
with or without NEM (Figure 1A, B, and G). This band is
likely to represent a phosphorylated form of MBD1. Notably,
the amounts of sumoylated MBD1 detectable by Western
blots were low, estimated to be only about 10% of the total
MBD1 protein, based on further experiments (not shown).
To investigate whether the 130 kDa protein recognized by
anti-MBD1 antibodies represents sumoylated MBD1, we per-
formed immunoprecipitations (IPs) with anti-MBD1, anti-
SUMO1 and anti-SUMO2/3 antibodies from HeLa nuclear
extracts. When anti-MBD1 antibodies were used to detect
immunoprecipitated proteins on Western blots, both the
70 kDa and the 130 kDa proteins could be seen in anti-
MBD1 IPs, while the anti-SUMO1 antibodies immunoprecipi-
tated only the 130 kDa MBD1 (Figure 1B). In the reverse
experiment, the anti-SUMO1 antibodies on Western blots also
detected only the 130 kDa band of anti-MBD1 IPs, suggesting
that this protein indeed represents SUMO1-modified MBD1
(Figure 1C). MBD1 was neither detectable among the proteins
immunoprecipitated with anti-SUMO2/3 antibodies nor
was the 130 kDa band in MBD1 IPs recognized by the
anti-SUMO2/3 antibodies (Figure 1B and D). From these
experiments, we conclude that MBD1 is SUMO1-modified
in HeLa cells.
Additionally, we used small interfering (si)RNAs to deplete
SUMO1, SUMO2 and SUMO3 or all SUMO proteins simulta-
neously in HeLa cells (Figure 1E and F). The 130 kDa MBD1
band was greatly reduced only when the cells received anti-
SUMO1 siRNA, further reinforcing our conclusion that in
HeLa MBD1 is modified by SUMO1 but not by SUMO2
or SUMO3 (Figure 1G).
MBD1 has two functional sumoylation sites
We next examined the amino-acid sequence of human MBD1
protein and found two potential sumoylation sites, both
VKQE, surrounding lysines 450 (K450) and 489 (K489) within
the C-terminus of MBD1 (Figure 2A). Alignment of MBD1
proteins from various mammalian species revealed that
the two potential sumoylation sites are highly conserved
(Figure 2B). Interestingly, although the C-terminus of
Xenopus tropicalis MBD1 is not homologous to human
MBD1 protein, it also contains two potential SUMO target
sites (IKEE and VKTE) surrounding lysines 446 and 471
(Supplementary Figure S1). The conservation of SUMO con-
jugation sites in MBD1 proteins of all vertebrates is consistent
Regulation of MBD1 by SUMO1
MJ Lyst et al
The EMBO Journal VOL 25 | NO 22 | 2006 &2006 European Molecular Biology Organization5318
with the idea that sumoylation of MBD1 may be functionally
important.
To investigate whether the VKQE sequences of human
MBD1 are essential for conjugation of SUMO1, we mutated
K450 and K489 or E452 and E491 to alanine and coexpressed
monomeric RFP-tagged wild-type and mutant proteins with
Flag-SUMO1 in HeLa cells. Ectopically expressed MBD1
proteins were analysed on Western blots with anti-RFP anti-
bodies (Figure 2C). Subsequently, we immunoprecipitated
the wild-type and the mutant RFP-MBD1 proteins and con-
firmed the identity of sumoylated forms on Western blots
with anti-SUMO1 antibodies (Figure 2D). As predicted, some
of the 130 kDa RFP-MBD1 was sumoylated, producing two
slow migrating bands of B190 and B140 kDa, while the
single mutations (K450A, K489A, E452A and K491A) pro-
duced only single additional band of B140 kDa (Figure 2C
and D). Therefore, we conclude that the 190 kDa protein is
MBD1 sumoylated at both lysine residues, while the 140 kDa
proteins are the monosumoylated forms of MBD1. We were
unable to detect SUMO1 conjugated to MBD1 carrying double
K to A or E to A point mutations (RFP-MBD12(K–A) and RFP-
MBD12(E–A); Figure 2C and D). Similar sumoylation patterns
could be observed with GST-MBD1 (wild type and mutants)
coexpressed in Escherichia coli with the SUMO conjugation
machinery (Supplementary Figure S2). Collectively, these
experiments demonstrate that the VKQE sequences are the
only functional sumoylation sites within MBD1. In addition,
the shift produced by SUMO1-modified RFP-MBD1 and the
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Figure 1 Sumoylation of MBD1 protein in vivo. (A) The anti-MBD1 antibodies detect an additional 130 kDa band in nuclear extracts prepared
with SUMO isopeptidase inhibitor NEM. (B) The anti-MBD1 antibodies recognize a 130 kDa band in SUMO1 but not in SUMO2/3 IPs.
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GST-MBD1 in E. coli is comparable to the B60 kDa shift of
sumoylated MBD1 observed in human cells. This suggests
that the endogenous MBD1 is normally modified by SUMO1
at both lysine residues.
SUMO conjugation sites are not essential for the
localization of MBD1 to nuclear foci
It has been reported that SUMO-modified transcription
factors are recruited to promyeloid leukaemia protein bodies
GFP-MBD1
GFP-MBD1
Overlay + DAPI
Overlay + DAPI
H. sapiens
M. musculus
R. norvegicus 
B. taurus
C. familiaris
H. sapiens
M. musculus
R. norvegicus 
B. taurus
C. familiaris
TRD
*
*
MBD TRDCxxCCxxC
1 557
450 489
VKQE VKQE
DNA binding DNA binding
CAF-1 interaction
SETDB1 binding
AM/MCAF binding
RF
P-
M
BD
1
RF
P-
M
BD
1
RF
P-
M
BD
1K
45
0A
RF
P-
M
BD
1K
45
0A
RF
P-
M
BD
1E
45
2A
RF
P-
M
BD
1E
49
1A
RF
P-
M
BD
1E
48
9A
RF
P-
M
BD
12
(K−
A)
RF
P-
M
BD
12
(E−
A)
RF
P-
M
BD
12
(K−
A)
RFP-MBD1
RFP-MBD1-
SUMO1
180
130
WB: α-RFP IP: α-RFP WB: α-SUMO1
180
130
100
kDa R
FP
-M
BD
1K
48
9A
kDa
RFP-MBD1K450A
RFP-MBD12(K−A)
403
425
425
397
105
463
485
485
457
165
−
A
B
C D
E F G
H I J
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and nuclear matrix attachment regions (Zhong et al, 2000;
Sachdev et al, 2001). Therefore, we asked whether sumoyla-
tion of MBD1, although seemingly low on Western blots,
might be important for the recruitment of MBD1 to some
specific nuclear compartments. In human cells, the endo-
genous MBD1, as well as GFP-tagged MBD1 expressed from
a transfected plasmid, accumulate in 6–7 nuclear foci, against
a background of diffuse nuclear staining (Figure 2E and H).
When we coexpressed GFP-tagged MBD1 and RFP-tagged
single (K450A, K489A) or double (2(K–A)) lysine mutants
of MBD1 in HeLa cells, the wild-type and mutant MBD1
proteins showed identical nuclear localization (Figure 2E–G
and H–J). Therefore, it seems unlikely that sumoylation
facilitates the recruitment of MBD1 protein to specific nuclear
domains.
PIAS1 and PIAS3 interact with the central portion of
MBD1
PIAS1 and PIAS3 proteins share B65% homology and
contain a SAR/Acinus/PIAS (SAP) putative DNA-binding
domain, a nuclear localization signal, a catalytic domain
known as SP-RING and a SUMO interaction motif (SIM)
(Figure 3A). To characterize in more detail the interactions
between MBD1 and PIAS proteins, we generated series of
PIAS1 and PIAS3 deletion constructs and tested them in yeast
two-hybrid assays for binding to full-length MBD1 (Supple-
mentary Figures S3 and S4). These interactions were inde-
pendently confirmed by GST-MBD1 pull-down assays with
in vitro translated HA-tagged full-length and truncated PIAS1
(Supplementary Figure S3). From these experiments, we
found that the C-terminus of PIAS1 (amino acids 510–651)
and the C-terminus of PIAS3 (amino acids 500–619) are
required for binding to MBD1 in vitro and in vivo.
To investigate further whether PIAS1 and PIAS3 bind to a
specific region of MBD1, we tested various MBD1 deletion
constructs in yeast two-hybrid assays with full-length PIAS1
and PIAS3 proteins (Figure 3B). As above, these interactions
were independently confirmed by pull-down assays with
GST-tagged truncated MBD1 proteins and in vitro translated
HA-tagged PIAS1 and PIAS3 (Figure 3C and D). From all
MBD1 deletion constructs, a protein containing the second
CxxC motif and the adjacent region of MBD1 (amino acids
221–480) was sufficient for binding of PIAS1 and PIAS3
in vitro and in vivo (Figure 3B–D). Notably, PIAS1 and
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PIAS3 binding overlaps with the first sumoylation site of
MBD1 at K450 and is in a close proximity to the second
sumoylation site at K489. This suggested to us that MBD1
may be a direct target for conjugation of SUMO1 by PIAS1
and PIAS3.
PIAS1 and PIAS3 are required for sumoylation of MBD1
in vivo
Because PIAS proteins interact with MBD1, we asked whether
PIAS1 and PIAS3 are responsible for sumoylation of MBD1
in vivo. We transfected HeLa cells with pools of siRNA
against PIAS1, PIAS3 or both PIAS1 and PIAS3 and analysed
the levels of PIAS proteins and sumoylation of MBD1 on
Western blots (Figure 4A–C). GL2 siRNA against firefly
luciferase was used as a control for nonspecific effects.
PIAS1 and PIAS3 siRNAs efficiently reduced the protein levels
of the respective PIAS protein compared to the controls
(Figure 4A). In both cases, the loss of a PIAS protein was
accompanied by a decrease in SUMO1-modified MBD1
(Figure 4B). However, MBD1-SUMO1 was no longer detect-
able on Western blots only when we depleted PIAS1 and
PIAS3 simultaneously (Figure 4B). This implies that both
PIAS proteins contribute to conjugation of SUMO1 to MBD1.
To investigate further whether an increase in the levels
of PIAS1 and PIAS3 would stimulate sumoylation of MBD1,
we transfected HeLa with plasmids expressing Flag-tagged
SUMO1 or co-transfected them with Flag-SUMO1 and GFP-
tagged either wild-type PIAS1 and PIAS3 or catalytically
inactive PIAS1C350S and PIAS3CS/HA (Long et al, 2004;
Munarriz et al, 2004) (Figure 4D). The cells were collected
2 days after the transfection and the levels of PIAS1, PIAS3
proteins and SUMO-modified MBD1 in the nuclear extracts
were examined. Western blots with anti-PIAS1 antibodies
detected both endogenous and GFP-tagged PIAS1, indicating
that the overall PIAS1 levels in transiently transfected cells
were approximately two-fold higher than in the controls
(Figure 4D, top panel). Both GFP-PIAS1 and GFP-PIAS3
were detectable with anti-GFP antibodies (Figure 4D, bottom
panel). Consistent with our binding assays and siRNA experi-
ments, we observed a significant increase in SUMO-modified
MBD1 in nuclear extracts of cells co-transfected either with
GFP-PIAS1 and Flag-SUMO1 or with GFP-PIAS3 and Flag-
SUMO1 (Figure 4E and F). We did not detect accumulation of
MBD1-SUMO1 in cells transfected with catalytically inactive
PIAS proteins (Figure 4E and F). The sumoylation of MBD1
by PIAS1 and PIAS3 seems to be specific, since transfections
with GFP-PIASy, another PIAS family protein, or Flag-SUMO1
alone did not induce accumulation of MBD1-SUMO (Supple-
mentary Figure S5). We also noticed that transfection of GFP-
PIAS1 or GFP-PIAS3 without Flag-SUMO1 was sufficient
to stimulate the sumoylation of MBD1 (Figure 5A and B
and Supplementary Figure S5). This indicates that the endo-
genous concentration of PIAS proteins rather than SUMO1
itself is limiting the sumoylation of endogenous MBD1. It also
implies that both PIAS1 and PIAS3 SUMO ligases are func-
tionally equivalent and can target MBD1 independently. In
principle, PIAS1 and PIAS3 could either directly sumoylate
MBD1 or stimulate sumoylation of MBD1 by some indirect
mechanism. Since PIAS proteins interact with MBD1 in vitro
and in vivo (see below), and their catalytic activities are
required for sumoylation of MBD1, these data collectively
suggest that MBD1 is a direct target for SUMO conjugation
by PIAS1 and PIAS3.
Sumoylation inhibits the formation of a complex
between MBD1 and SETDB1
Sumoylation of target proteins can affect the assembly of
specific protein complexes by either promoting or disrupting
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protein–protein interactions (Johnson, 2004). Our evidence
that SUMO1 is usually conjugated to both K450 and K489 of
MBD1 in human cells led us to investigate whether sumoy-
lated MBD1 is able to interact with its partner proteins,
SETDB1 and CAF-1. We have previously shown that in
HeLa cells MBD1 forms a stable complex with SETDB1
throughout the cell cycle, and with chromatin assembly
factor CAF-1 specifically in S-phase (Sarraf and Stancheva,
2004). The region of MBD1 interacting with SETDB1 (amino
acids 221–480) contains the first sumoylation site of MBD1
at K450. Notably, the SETDB1 binding region of MBD1 also
overlaps with the amino acids required for PIAS1/PIAS3
binding (Figures 2A and 3B). The TRD of MBD1 (amino
acids 480–546) includes the second sumoylation site at K489
and is known to recruit the SETDB1 cofactor AM/MCAF1
(Fujita et al, 2003a). Thus, it is reasonable to speculate that
sumoylation of MBD1 may affect SETDB1 and/or AM bind-
ing. On the other hand, CAF-1 binds to the N-terminus of
MBD1, which is far from the sumoylatable lysines and may
not be affected by conjugation of SUMO to MBD1 (Figure 2A).
To establish whether sumoylated MBD1 interacts with
SETDB1 and CAF-1, we transfected HeLa with either GFP-
PIAS1, GFP-PIAS3 or co-transfected them with GFP-PIAS1
and Flag-SUMO1 to achieve accumulation of MBD1-SUMO1.
Both unmodified MBD1 and sumoylated MBD1 were easily
detectable in the transfected cells with anti-MBD1 antibodies
(Figure 5A and B, IP supernatants). We synchronized the
cells in the S-phase, prepared nuclear extracts and immuno-
precipitated SETDB1 and CAF-1 (Figure 5A and B, IP pellet).
In SETDB1 IPs, the nonsumoylated MBD1 readily co-immu-
noprecipitated with SETDB1, as detected by anti-MBD1 anti-
bodies (Figure 5A, IP pellet). By contrast, the MBD1-SUMO
was not detectable in SETDB1 IPs either by anti-MBD1 or by
anti-Flag antibodies and always remained in the supernatants
(Figure 5A, IP supernatant). CAF-1 antibodies immunopreci-
pitated both MBD1 and MBD1-SUMO (Figure 5B, IP pellets).
Confirming our previous findings, only about 30% or less of
MBD1 protein in the S-phase extracts co-immunoprecipitated
with CAF-1. Therefore, significant amounts of unmodified
and sumoylated MBD1 remain in the supernatants after
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IP with anti-CAF-1 antibodies (Figure 5B, IP supernatant).
From these experiments, it is clear that MBD1-SUMO1 does
not interact efficiently with SETDB1 but still can bind to
CAF-1 in the S-phase.
Downregulation of SETDB1 leads to accumulation
of MBD1-SUMO
In earlier studies, we found that most of the MBD1
co-immunoprecipitates with SETDB1 from HeLa nuclear
extracts (Sarraf and Stancheva, 2004). Since PIAS proteins
and SETDB1 share the same region of MBD1 for binding, we
hypothesized that the formation of a complex between MBD1
and SETDB1 might protect MBD1 against conjugation of
SUMO1 by the endogenous PIAS1 or PIAS3. To test this, we
used siRNA to reduce SETDB1 protein levels in HeLa and
asked whether MBD1-SUMO1 accumulates in these cells. GL2
siRNA served as a control. Western blots with anti-SETDB1
antibodies showed that 2 and 4mg of SETDB1 siRNA, but not
the equivalent amounts of GL2 siRNA, reduced SETDB1
protein to about 40 and 10%, respectively, compared to the
controls (Figure 5C). In the same extracts, Western blots with
anti-MBD1 antibodies detected a dose-dependent accumula-
tion of MBD1-SUMO1 in cells treated with SETDB1 siRNA but
not with GL2 siRNA (Figure 5C). Neither SETDB1 nor GL2
siRNA led to the upregulation of PIAS1 or PIAS3 protein
levels, or had a general effect on SUMO1-modified proteins
as the sumoylation of RanGAP1 remained unchanged
(Figure 5C). Consistent with accumulation of MBD1-SUMO1
in cells treated with SETDB1 siRNA, MBD1 co-immuno-
precipitated more efficiently with PIAS proteins when
SETDB1 levels were reduced (Supplementary Figure S6).
In summary, these experiments demonstrate that SETDB1
protein, when present in HeLa cell, competes against PIAS1
and PIAS3 for binding to MBD1 and thus protects MBD1
from targeting by the SUMO modification machinery. Given
that most of the MBD1 in HeLa is in complex with SETDB1,
this may explain why only a small proportion of MBD1 is
sumoylated in these cells (Figure 1A).
The inhibition of SETDB1 binding to MBD1 by SUMO1
should result in a detectable decrease of MBD1-associated
HMT activity comparable to that observed in SETDB1-
depleted cells (Sarraf and Stancheva, 2004). To test this, we
immunoprecipitated MBD1 from nuclear extracts prepared
from cells transfected either with GFP-PIAS1, GFP-PIAS3,
GFP-PIAS3CS/HA or from cells treated with SETDB1 and GL2
siRNAs. These IPs were further used for in vitro histone
methylation assays using recombinant histone H3 N-terminal
tails as a substrate for incorporation of 3H-labelled methyl
groups (Figure 5D). In agreement with our previous results,
MBD1 IPs from cells transfected with GFP-PIAS1 or GFP-
PIAS3 or from cells treated with SETDB1 siRNA showed
significantly reduced histone methylation activity compared
to the controls (Figure 5D). This in turn led us to investigate
whether transcriptional repression by MBD1 is compromised
in cells with elevated levels of MBD1-SUMO1.
Sumoylation antagonizes MBD1-mediated
transcriptional repression
We have previously shown that MBD1/SETDB1 complex
methylates chromatin at K9 of histone H3 to silence tran-
scription of the MBD1 target gene p53BP2 in HeLa (Sarraf and
Stancheva, 2004). Efficient transcriptional repression by
MBD1 requires interaction with SETDB1 protein, since
p53BP2 is aberrantly expressed in cells treated with
SETDB1 siRNA (Sarraf and Stancheva, 2004). Given that
MBD1-SUMO1 did not interact with SETDB1, we asked
whether accumulation of MBD1-SUMO1 in cells overexpres-
sing PIAS1 might lead to the loss of p53BP2 silencing and
thus mirror the effect of SETDB1 siRNA. Therefore, we
compared the expression of p53BP2 in cells co-transfected
with SETDB1 siRNA to that in cells co-transfected with GFP-
PIAS1 and Flag-SUMO1 (Figure 6B, p53BP2). As a control, we
co-transfected cells with catalytically inactive GFP-PIAS1C350S
and Flag-SUMO1. In all experiments, we used the constitu-
tively expressed glyseraldehyde-3-phosphate dehydrogenase
(GAPDH) gene as a control for nonspecific effects (Figure 6B,
GAPDH). Consistent with our previous observations, p53BP2
expression was detectable in cells treated with SETDB1
siRNA. Neither PIAS1/3 siRNA nor SUMO1/2/3 siRNA led
to aberrant expression of p53BP2. In contrast, transfections
with PIAS1 and Flag-SUMO1 but not with PIAS1C350S and
Flag-SUMO1 upregulated p53BP2 transcription to levels com-
parable to those seen in SETDB1 siRNA-treated cells
(Figure 6B). Thus, sumoylation of MBD1 by PIAS1 not only
inhibits SETDB1 binding but also disrupts transcriptional
repression of p53BP2 gene normally mediated by the
MBD1/SETDB1 complex.
We further hypothesized that a form of MBD1 with both
sumoylatable lysines mutated to alanine (MBD12(K–A))
should not be a target of the SUMO conjugation machinery
and might rescue the repression of p53BP2 in PIAS1-over-
expressing cells. We co-transfected cells with GFP-PIAS1,
Flag-SUMO1 and either RFP-MBD12(K–A) or RFP-MBD1 and
analysed them for p53BP2 expression. In parallel, we inves-
tigated the single lysine mutants of MBD1 (MBD1K450A and
MBD1K489A) to determine the contribution of individual
sumoylation sites for the regulation of MBD1-mediated
repression by SUMO. All RFP-MBD1 proteins showed com-
parable expression in the transfected cells (Supplementary
Figure S7). However, only the nonsumoylatable MBD12(K–A)
but not RFP-MBD1 could successfully rescued p53BP2 repres-
sion in PIAS1-overexpressing cells (Figure 6B). MBD1K450A
and MBD1K489A were not as efficient as MBD12(K–A) in silen-
cing p53BP2 (Figure 6B). Collectively, these experiments
demonstrate that conjugation of SUMO to either one of the
two sumoylatable lysines of MBD1 results in disruption of
MBD1-mediated repression of p53BP2.
SETDB1-mediated H3K9 methylation of p53BP2
promoter is lost in PIAS1-overexpressing cells
Recruitment of the MBD1/SETDB1 complex to the p53BP2
promoter in HeLa cells establishes transcriptionally repres-
sive chromatin trimethylated at K9 of histone H3 (Sarraf and
Stancheva, 2004). Given that sumoylation of MBD1 by PIAS1
inhibited binding of SETDB1 to MBD1 and induced p53BP2
transcription, we examined whether this is accompanied by
loss of MBD1, SETDB1 and H3K9 methylation from the
promoter of the p53BP2. Chromatin immunoprecipitations
(ChIP) with anti-MBD1 antibodies detected approximately
equal amounts of MBD1 bound to the p53BP2 promoter in
nontransfected cells, cells transfected with GFP-PIAS1, GFP-
PIAS1 and Flag-SUMO1, and in control cells transfected
with PIAS1C350S and Flag-SUMO1 (Figure 6C, a-MBD1).
Thus, accumulation of MBD1-SUMO1 in cells overexpressing
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PIAS1 does not affect MBD1 binding to the p53BP2 promoter.
A sequential pull down of MBD1-enriched chromatin
(immunoprecipitated with antibodies against MBD1) with
anti-SUMO1 and anti-Flag antibodies detected SUMO1-mod-
ified MBD1 bound to p53BP2 sequences in cells transfected
with PIAS1 and PIAS1/SUMO1 but not in the control cells
(Figure 6C, a-SUMO1, a-Flag). This indicates that MBD1-
SUMO is not impaired in binding to methylated DNA and
localizes to the endogenous MBD1 binding sites. However,
ChIP with anti-SETDB1 and anti-trimethyl H3K9 anti-
bodies detected reduced amounts of SETDB1 at the p53BP2
promoter, as well as reduced H3K9 methylation of p53BP2
promoter chromatin, in cells transfected with PIAS1 and
PIAS1/SUMO1 as compared to the controls (Figure 6C,
a-SETDB1, a-H3K9me3). In summary, these experiments
demonstrate that sumoylated MBD1, although capable of
binding to methylated DNA, is unable to recruit SETDB1
HMT to chromatin. This results in the loss of the repressive
histone modification and aberrant expression of p53BP2.
Discussion
MBD1 is targeted for sumoylation by PIAS1 and PIAS3
proteins
Post-translational modifications such as phosphorylation,
ubiquitination, acetylation and sumoylation often contribute
to the regulation of protein function and stability. Here we
demonstrate that the methyl-CpG-binding protein MBD1 is
SUMO1-modified in human cells at lysines K450 and K489
within two conserved SUMO conjugation sites (VKQE). These
two sequences seem to be the only functional sumoylation
sites within MBD1, since mutant MBD1 proteins with either
lysines 450 and 489 or glutamates 452 and 491 mutated to
alanine cannot be sumoylated in HeLa or in E. coli expressing
mammalian SUMO conjugation enzymes. The conservation
of sumoylation sites between amphibian and human MBD1,
within a region that shows overall poor amino-acid similarity,
suggests that SUMO conjugation to MBD1 might be function-
ally important in all vertebrate species.
In search of enzymatic activities that target MBD1 for
sumoylation, we found that two E3 SUMO ligases, PIAS1
and PIAS3, which we initially identified in a yeast two-hybrid
screen, are required for the conjugation of SUMO1 to MBD1
as revealed by RNAi experiments. Both PIAS proteins, when
expressed above their endogenous levels in HeLa, efficiently
target MBD1 for SUMO conjugation. It is likely that SUMO is
transferred directly from PIAS1 or PIAS3 to MBD1 since
catalytically inactive PIAS1C350S and PIAS3CS/HA did not
lead to accumulation of MBD1-SUMO in vivo. PIAS1 and
PIAS3 share significant homology within their functional SAP
and SP-RING domains (Figure 3A). However, the least con-
served C-terminal regions of both PIAS proteins bind to
MBD1 in vitro and in yeast two-hybrid assays. On the other
hand, another PIAS family protein, PIASy, neither interacts
with MBD1 nor stimulates sumoylation of MBD1 in HeLa
cells. Characteristically for transient enzyme–substrate inter-
actions, the endogenous MBD1 and PIAS1 or PIAS3 do not
immunoprecipitate efficiently from HeLa nuclear extracts. We
could detect an interaction between the endogenous MBD1
and PIAS proteins only when the levels of SETDB1 protein
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were reduced by siRNA (Supplementary Figure S6). There-
fore, it is unlikely that PIAS1 and PIAS3 form a stable
complex with MBD1.
Properties of sumoylated MBD1 protein
A number of studies demonstrate that sumoylation of nuclear
proteins can affect their localization and function (Johnson,
2004; Hay, 2005). The presence of sumoylated MBD1 in all
human cells lines examined, and accumulation of MBD1-
SUMO in cells overexpressing PIAS1 or PIAS3, prompted us
to investigate the properties of SUMO1-modified MBD1. As
a starting point, we established that the sumoylation sites
of MBD1 are not essential for the localization of MBD1
to nuclear foci. A mutant MBD1 protein MBD12(K–A), with
both sumoylatable lysines replaced by alanine, displays
localization indistinguishable from that of the wild-type
MBD1 including in cells that overexpress PIAS proteins (not
shown). Our subsequent analyses by ChIP demonstrate that
MBD1-SUMO binds as well as unmodified MBD1 to known
endogenous MBD1 binding sites such as the p53BP2 promo-
ter. Given that the sumoylatable lysines K450 and K489 are
not located within the two DNA-binding domains of MBD1, it
is unlikely that MBD1-SUMO1 has DNA-binding properties
unique to the modified protein. However, it is still possible
that conjugation of SUMO1 induces subtle conformational
changes that affect the affinity of MBD1 for some specific
genomic sequences. In the future, it might be of interest to
investigate in more detail the binding preferences of MBD1-
SUMO1.
As post-translational protein modifications, including
sumoylation, can either promote or inhibit the assembly of
specific protein complexes, we investigated whether MBD1-
SUMO1 binds its partner proteins. Interestingly, we found
that MBD1-SUMO1 readily co-immunoprecipitates from HeLa
nuclear extracts with chromatin assembly factor CAF-1 p150,
but not with SETDB1 HMT. Consistently, MBD1 immuno-
precipitates from PIAS1- or PIAS3-overexpressing cells have
reduced HMT activity. Given that the sumoylation sites of
MBD1 overlap with or are in close proximity to the region
of SETDB1 binding (Figure 2A), one could hypothesize that
SUMO1 conjugated to MBD1 interferes sterically with
SETDB1 binding. However, preliminary in vitro binding
experiments indicate that bacterially expressed GST-MBD1
and GST-MBD1-SUMO1 interact with SETDB1 equally well
(Supplementary Figure S8). Therefore, the inhibition of
SETDB1 binding to MBD1-SUMO in vivo may either involve
additional proteins that preferentially recognize MBD1-
SUMO1 but do not bind to MBD1 or, alternatively, sumoy-
lation may promote subsequent post-translational modifica-
tions of MBD1 that are inhibitory to SETDB1 binding.
While this manuscript was under review, it was reported
that AM/MCAF1, a protein that binds to and regulates
SETDB1, preferentially interacts with SUMO2/3-modified
MBD1 in vitro (Uchimura et al, 2006). These findings have
led to the suggestion that conjugation of SUMO2/3 to MBD1
could promote the recruitment of SETDB1 to MBD1 via
MCAF1 and thus result in the stabilization of heterochromatic
loci, in contrast to our observations that conjugation of
SUMO1 to MBD1 disrupts the interaction with SETDB1.
Whether SUMO2/3 modification of MBD1 is required for
MCAF1 binding in vivo clearly requires further investigation,
because of the interesting possibility that conjugation of
SUMO1 and SUMO2/3 may have opposing effects on
MBD1-associated corepressor complexes. However, we
note that, unlike Uchimura et al (2006), we failed to detect
any SUMO2/3-modified MBD1 under our experimental con-
ditions. The reasons for these differing results may be due
to the specific cell types and/or growth conditions used.
Regulation of MBD1-mediated repression by a
competitive binding of PIAS and SETDB1 proteins
to MBD1
The functional significance of SUMO1 conjugation to MBD1
became apparent when we investigated the expression of an
MBD1 target gene, p53BP2, in cells overexpressing PIAS1.
Normally, MBD1 binds to methylated DNA at the promoter
of p53BP2 and represses transcription via recruitment of
SETDB1, which methylates chromatin at K9 of histone H3.
In cells overexpressing PIAS1, MBD1-SUMO1 is still bound to
p53BP2 promoter but no longer recruits SETDB1. This results
in a decrease of H3K9 methylation and aberrant transcription
of p53BP2 gene. Interestingly, only the MBD12(K–A) protein
with both sumoylatable lysines replaced by alanine, but not
the MBD1 proteins carrying single lysine mutations, could
rescue the repression of p53BP2 in PIAS1-overexpressing
cells. This implies that sumoylation of either lysine, K450
or K489 is sufficient to abrogate transcriptional silencing
mediated by MBD1. On the other hand, MBD1 seems to be
protected from conjugation of SUMO when it is in complex
with SETDB1. Thus in cells treated with SETDB1 siRNA,
MBD1 is more readily available to the sumoylation machin-
ery. Notably, the upregulation of p53BP2 in PIAS1-over-
expressing cells is comparable to the level of p53BP2 expres-
sion in cells treated with SETDB1 siRNA. Taken together,
these observations suggest the existence of a finely balanced
mechanism to regulate transcriptional repression by MBD1,
which operates through SETDB1 and PIAS proteins compet-
ing for binding to MBD1 (Figure 7). Assuming that MBD1
levels are constant, as they were throughout our experiments,
the outcome of this competition, and therefore the ability of
MBD1 to repress transcription, would be dependent on the
concentration of SETDB1 and PIAS proteins. Thus, the for-
mation of a repressive MBD1/SETDB1 complex should be
favored in cells where either SETDB1 protein levels are high
or PIAS1 and PIAS3 levels are low (Figure 7A). Conversely,
high levels of PIAS1 and/or PIAS3 or low levels of SETDB1
should result in SUMO ligases competing more efficiently
against SETDB1 for binding to MBD1 (Figure 7B). Ultimately,
the interaction of MBD1 with PIAS proteins should lead to
sumoylation of MBD1, inhibition of complex formation
between MBD1 and SETDB1, and inefficient repression of
MBD1 target genes. It is to be expected that the activation of
transcription following sumoylation of MBD1 would
require the repressive H3K9 methylation to be removed
from chromatin. Given that sumoylated MBD1 binds to
CAF-1 but no longer recruits SETDB1 to methylate newly
assembled nucleosomes, it is likely that the efficient expres-
sion of MBD1 target genes may require the passage of
the cells through the S phase. Alternatively, H3K9 methyla-
tion may be removed by either histone H3 exchange con-
comitant with transcriptional activation or by an enzymatic
H3K9 demethylation activity that is recruited to MBD1-
SUMO1. Further experiments will address these interesting
possibilities.
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In conclusion, we have shown that conjugation of SUMO1
to MBD1 by PIAS family proteins inhibits the formation of a
complex between MBD1 and SETDB1 HMT and antagonizes
MBD1/SETDB1-mediated repression. Our data are consistent
with a model where the function of MBD1 in transcriptional
repression and maintenance of silenced chromatin is regu-
lated by SETDB1 and PIAS proteins competing for binding
to MBD1. Such a flexible mechanism to regulate MBD1-
mediated repression may be particularly important during
embryonic development, when gene expression in various
lineages of differentiating cells is switched on or off.
Additionally, aberrant methylation of CpG islands in cells
undergoing tumorigenic transformation may require a rein-
forced potential of MBD1 to silence transcription, which
could be achieved by downregulation of PIAS proteins.
Notably, aberrantly high or aberrantly low expression of
PIAS1 and PIAS3 has been detected human tumours and
may contribute to the progression of the disease (Beer et al,
2002; Lapointe et al, 2004; Wang and Banerjee, 2004).
Materials and methods
Plasmids and transient transfections
Point mutations in MBD1, PIAS1 and PIAS3 were generated by
mutagenic PCR. To generate catalytically inactive PIAS proteins, we
mutated cysteine 350 in the SP-RING domain of PIAS1 to serine
(PIAS1C350S) and cysteine 334 and histidine 336 in the catalytic
domain of PIAS3 to serine and alanine respectively (PIAS3CS/HA).
PIAS1, PIAS3 (wild type and mutants) and PIASy were cloned into
pEGFP-C3 vector in frame with the N-terminal EGFP. MBD1 (wild
type and mutants) were cloned into pRFP-N1 in frame with a
C-terminal monomeric RFP (mCherry) protein (Shaner et al, 2004).
pFlag-SUMO1 plasmid was a gift from Hong Wu, UCLA. siRNA
SMART pools designed against SUMO1, SUMO2, SUMO3, PIAS1
and PIAS3 were purchases from Dharmacon. SETDB1 siRNA target
sequence was described earlier (Wang et al, 2003). Five hundred
nanograms of each plasmid or 4mg of siRNA were transiently
transfected into 1.5106 HeLa cells using Nucleofection kit R and
Nucleofector device (Amaxa Biosystems). The cells were grown in
standard supplemented DMEM medium on 10 cm dishes for 48 h
and collected for preparation of nuclear extracts. In most siRNA
experiments, the cells were transfected twice with a 2-day interval
between the two transfections.
Antibodies and co-IP assays
The preparation of nuclear extracts and co-IPs were performed
according to standard procedures. Where appropriate, NEM was
added to 10 mM into all buffers used for preparation of nuclear
extracts and IP washes. Western blots were performed according to
the standard protocols. The antibodies used for IPs and Western
blots were anti-MBD1 IMG-306 (TCS Cell Works), anti-Flag M2
(Sigma), anti-CAF-1, anti-GFP, anti-HA (provided by CRUK),
anti-SETDB1 (Upstate), anti-RFP (Clontech), anti- PIAS1 sc8152,
anti-SUMO 1 sc5308, anti-SUMO2/3 sc32873 (Santa Cruz Biotech-
nology) and anti-PIAS3 (Abcam).
In vitro pull downs
GST-tagged MBD1 deletion constructs and pull-down procedure
were described previously (Sarraf and Stancheva, 2004). pGADT7-
PIAS1 and pGADT7-PIAS3 were translated in rabbit reticulocyte
lysates (TnT T7 kit, Promega). Hundred nanograms of each GST-
MBD1 protein and 1ml of translated PIAS1 or PIAS3 were used in
the pull-down experiments.
Histone methylation assays
Histone methylation assays with MBD1 immunoprecipitates were
performed as described previously (Sarraf and Stancheva, 2004).
Recombinant GST-tagged histone H3 N-terminal peptide containing
amino acids 1–54 was used as a substrate (Tachibana et al, 2001).
The incorporation of 3H-methyl groups by the immunoprecipitated
MBD1 complexes was measured by scintillation counting (Perkin-
Elmer) and analysed on 12% SDS gels by autoradiography.
RT–PCR
RNA purification, reverse transcription and PCRs were performed
as described elsewhere (Sarraf and Stancheva, 2004).
ChIP
Chromatin IPs were performed as described in Sarraf and Stancheva
(2004). For re-ChIP immunoprecipitated chromatin from the first IP
(scaled 3 ) was removed from protein G sepharose by adding SDS
to 1% and incubation for 15 min at room temperature. The samples
were diluted to 0.1% SDS and subjected to a second round of IP and
washes. Additional antibodies (to these above) used for ChIP assays
were anti-H3K9me3 (provided by P Singh) and anti-H3 (Upstate).
Microscopy
Transfected HeLa cells were grown on 15 mm coverslips in DMEM,
fixed with 4% paraformaldehyde in PBS, mounted in vectashield
and observed by Olympus BX61 microscope equipped with Color-
ViewII CCD camera and AnalySIS software for image capture.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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Figure 7 Regulation of MBD1-mediated repression by a competition between PIAS proteins and SETDB1. (A) The formation of the MBD1/
SETDB1 repressive complex would be favoured in cells expressing low levels of PIAS1 or PIAS3. (B) PIAS1 and PIAS3 would compete more
efficiently against SETDB1 if their expression is high. This would result in the conjugation of SUMO1 to MBD1 and a decrease of the repressive
MBD1/SETDB1 complex. In order to achieve efficient expression of target genes, H3K9 methylation has to be removed from chromatin by
either the cells undergoing a round of DNA replication or by some alternative mechanism.
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